Dergiler / Medicine Science / 2014 / Cilt: 3 - Sayı: 4

Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients

Sayfa
1655–1674
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, silymarin treatment failed to significantly affect liver function tests.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Hepatitis C virus is a major public health problem causing significant morbidity and mortality.
📊
Temel Bulgular & Veri:Until recently, the standard treatment with peginterferon and ribavirin was far from being perfect due to its cost, poor tolerability and low sustained virological rates (SVR) rates.
💡
Sonuç & Katkı:However, silymarin treatment failed to significantly affect liver function tests.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Hepatitis C virus is a major public health problem causing significant morbidity and mortality. Until recently, the standard treatment with peginterferon and ribavirin was far from being perfect due to its cost, poor tolerability and low sustained virological rates (SVR) rates. Although, the novel direct-acting antiviral agents (DAAs) telaprevir, and boceprevir has dramatically improved SVR rates; issues such as adverse reactions, frequent dosing, and drug interactions still represent a challenge. Even overcoming these challenges with the new revolutionary development of sofosbuvir, its high cost still needs to be addressed. Therefore, the popularity of alternative medicines in chronic hepatitis C (CHC) treatment such as silymarin and ursodeoxycholic acid (UDCA) has increased. The multiple hepatoprotective effects of these drugs have made them attractive for evaluation in patients with different liver diseases. The aim of this study is to compare the hepatoprotective effect of silymarin, UDCA, and a combination therapy of both in chronic hepatitis C patients. Forty CHC patients (32 males and 8 females) were recruited from hepatology clinic at Beni-Suef University. Patients were divided randomly into four equal groups of tens A, B, C and D, who received 420 mg/day silymarin capsules, 500 mg/day UDCA capsules, combined therapy of both, and a placebo treatment, respectively. Serum liver parameters were measured at baseline and repeated 12 weeks after therapy.A statistically significant improvement in mean serum levels of ALT, AST, and bilirubin was obtained with UDCA therapy either when administered alone or combined with silymarin. However, silymarin treatment failed to significantly affect liver function tests.

🔖

Bu Makaleye Atıf Yap

MENSHAWE, S. F. E., AHMED, A. S., ABDELATY, L. N., ABOSEİF, M. A. (2014). Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients. Medicine Science, Cilt: 3 - Sayı: 4, 1655–1674. https://ajindex.com/articles/277941

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Tong MJ, El-Farra NS, Reikes AR. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332(22):1463-6
  2. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992;327(27):1906-11
  3. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology.1997; 112(2): 463-72
  4. Keating GM, Vaidya A, Sofosbuvir: first global approval. Drugs. 2014;74(2):273- 82
  5. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013;13: 288
  6. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013;28(1):38-45
  7. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, 8. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195- 206
  8. Flamm SL, Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. Gastroenterol Hepatol (NY). 2013;9(10):682-3
  9. Pockros PJ. Interferon-free hepatitis C therapy: how close are we? Drugs. 2012;72:1825-31. 11.Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, AbdelHamid M, Shehata M, Abu-Baki L, Medhat A, Magder LS, Afdhal NH, Strickland GT. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004;36(11):752-9
  10. Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem. 2013;20(30):3733-42
  11. Omar M. Chronic Hepa